{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:33:21Z","timestamp":1790609601915,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"DOI":"10.7759\/cureus.109712","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:38:35Z","timestamp":1779863915000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative Augmentative Efficacy of Second-Generation Antipsychotics in Adult Treatment-Resistant Depression: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Rashed","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gihad","family":"Elbashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayada","family":"Abdulbagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01040-7","article-title":"The growing burden of major depressive disorders (MDD): implications for researchers and policy makers","volume":"39","author":"Proudman D","year":"2021","unstructured":"Proudman D, Greenberg P, Nellesen D. The growing burden of major depressive disorders (MDD): implications for researchers and policy makers. Pharmacoeconomics. 2021, 39:619-25. 10.1007\/s40273-021-01040-7","journal-title":"Pharmacoeconomics"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02622-x","article-title":"The economic burden of adults with major depressive disorder in the United States (2019)","volume":"40","author":"Greenberg P","year":"2023","unstructured":"Greenberg P, Chitnis A, Louie D, et al.. The economic burden of adults with major depressive disorder in the United States (2019). Adv Ther. 2023, 40:4460-79. 10.1007\/s12325-023-02622-x","journal-title":"Adv Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00454-1","article-title":"Major depressive disorder","volume":"9","author":"Marx W","year":"2023","unstructured":"Marx W, Penninx BW, Solmi M, Furukawa TA, Firth J, Carvalho AF, Berk M. Major depressive disorder. Nat Rev Dis Primers. 2023, 9:44. 10.1038\/s41572-023-00454-1","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313070","article-title":"Augmentative pharmacological strategies in treatment-resistant major depression: a comprehensive review","volume":"22","author":"Caldiroli A","year":"2021","unstructured":"Caldiroli A, Capuzzi E, Tagliabue I, et al.. Augmentative pharmacological strategies in treatment-resistant major depression: a comprehensive review. Int J Mol Sci. 2021, 22:13070. 10.3390\/ijms222313070","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.prcp.20200004","article-title":"Updating the comparative evidence on second\u2010generation antipsychotic use with schizophrenia","volume":"2","author":"McDonagh MS","year":"2020","unstructured":"McDonagh MS, Dana T, Selph S, et al.. Updating the comparative evidence on second\u2010generation antipsychotic use with schizophrenia. Psychiatr Res Clin Pract. 2020, 2:76-87. 10.1176\/appi.prcp.20200004","journal-title":"Psychiatr Res Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034670","article-title":"Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: a systematic review and network meta-analysis","volume":"102","author":"Wang J","year":"2023","unstructured":"Wang J, Li W, Li M, Wu H, Qiu Z. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: a systematic review and network meta-analysis. Medicine (Baltimore). 2023, 102:e34670. 10.1097\/MD.0000000000034670","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.956081","article-title":"Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants","volume":"10","author":"Italiano D","year":"2014","unstructured":"Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014, 10:1457-89. 10.1517\/17425255.2014.956081","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2348561","article-title":"A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective","volume":"23","author":"Strube W","year":"2024","unstructured":"Strube W, Wagner E, Luykx JJ, Hasan A. A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective. Expert Opin Drug Saf. 2024, 23:715-29. 10.1080\/14740338.2024.2348561","journal-title":"Expert Opin Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2018.05.009","article-title":"Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential","volume":"78","author":"Buys ES","year":"2018","unstructured":"Buys ES, Zimmer DP, Chickering J, et al.. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide. 2018, 78:72-80. 10.1016\/j.niox.2018.05.009","journal-title":"Nitric Oxide"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2024.32","article-title":"A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder","volume":"37","author":"McIntyre RS","year":"2024","unstructured":"McIntyre RS, Sundararajan K, Behl S, et al.. A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder. Acta Neuropsychiatr. 2024, 37:e33. 10.1017\/neu.2024.32","journal-title":"Acta Neuropsychiatr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13615","article-title":"Adjunctive brexpiprazole 1\u2009mg and 2\u2009mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2\/3, randomized, double-blind (BLESS) study","volume":"78","author":"Kato M","year":"2024","unstructured":"Kato M, Shiosakai M, Kuwahara K, et al.. Adjunctive brexpiprazole 1\u2009mg and 2\u2009mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2\/3, randomized, double-blind (BLESS) study. Psychiatry Clin Neurosci. 2024, 78:113-22. 10.1111\/pcn.13615","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220504","article-title":"Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"180","author":"Sachs GS","year":"2023","unstructured":"Sachs GS, Yeung PP, Rekeda L, Khan A, Adams JL, Fava M. Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry. 2023, 180:241-51. 10.1176\/appi.ajp.20220504","journal-title":"Am J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14643","article-title":"Cariprazine for the adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant therapy: results of a randomized, double-blind, placebo-controlled study","volume":"84","author":"Riesenberg R","year":"2023","unstructured":"Riesenberg R, Yeung PP, Rekeda L, Sachs GS, Kerolous M, Fava M. Cariprazine for the adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2023, 84:10.4088\/JCP.22m14643","journal-title":"J Clin Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1430220","article-title":"Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study","volume":"34","author":"Hobart M","year":"2018","unstructured":"Hobart M, Skuban A, Zhang P, et al.. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin. 2018, 34:633-42. 10.1080\/03007995.2018.1430220","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m12058","article-title":"A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg\/d as adjunctive treatment of adults with major depressive disorder","volume":"79","author":"Hobart M","year":"2018","unstructured":"Hobart M, Skuban A, Zhang P, et al.. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg\/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018, 79:10.4088\/JCP.17m12058","journal-title":"J Clin Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder","volume":"77","author":"Durgam S","year":"2016","unstructured":"Durgam S, Earley W, Guo H, et al.. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016, 77:371-8. 10.4088\/JCP.15m10070","journal-title":"J Clin Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4578","article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial","volume":"48","author":"Earley WR","year":"2018","unstructured":"Earley WR, Guo H, N\u00e9meth G, Hars\u00e1nyi J, Thase ME. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull. 2018, 48:62-80. 10.64719\/pb.4578","journal-title":"Psychopharmacol Bull"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Fava M","year":"2018","unstructured":"Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, N\u00e9meth G. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018, 33:312-21. 10.1097\/YIC.0000000000000235","journal-title":"Int Clin Psychopharmacol"},{"key":"ref21","article-title":"The efficacy of quetiapine XR as an adjunctive therapy to duloxetine in depressed patients with inadequate response to monotherapy","volume":"66","author":"Moica T","year":"2018","unstructured":"Moica T, Grecu IG, Sab\u0103u D, et al.. The efficacy of quetiapine XR as an adjunctive therapy to duloxetine in depressed patients with inadequate response to monotherapy. Farmacia. 2018, 66:354-7.","journal-title":"Farmacia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12663","article-title":"Randomized, double-blind comparison of aripiprazole\/sertraline combination and placebo\/sertraline combination in patients with major depressive disorder","volume":"72","author":"Kamijima K","year":"2018","unstructured":"Kamijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y. Randomized, double-blind comparison of aripiprazole\/sertraline combination and placebo\/sertraline combination in patients with major depressive disorder. Psychiatry Clin Neurosci. 2018, 72:591-601. 10.1111\/pcn.12663","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09688","article-title":"Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants","volume":"76","author":"Thase ME","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, et al.. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015, 76:1224-31. 10.4088\/JCP.14m09688","journal-title":"J Clin Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120953983","article-title":"Antidepressant responses in direct comparisons of melancholic and non-melancholic depression","volume":"34","author":"Undurraga J","year":"2020","unstructured":"Undurraga J, V\u00e1zquez GH, Tondo L, Baldessarini RJ. Antidepressant responses in direct comparisons of melancholic and non-melancholic depression. J Psychopharmacol. 2020, 34:1335-41. 10.1177\/0269881120953983","journal-title":"J Psychopharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis","volume":"76","author":"Zhou X","year":"2015","unstructured":"Zhou X, Ravindran AV, Qin B, et al.. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015, 76:e487-98. 10.4088\/JCP.14r09204","journal-title":"J Clin Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008121.pub2","article-title":"Second-generation antipsychotics for major depressive disorder and dysthymia","volume":"2010","author":"Komossa K","year":"2010","unstructured":"Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010, 2010:CD008121. 10.1002\/14651858.CD008121.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.006","article-title":"Augmentation with atypical antipsychotics for treatment-resistant depression","volume":"280","author":"Cant\u00f9 F","year":"2021","unstructured":"Cant\u00f9 F, Ciappolino V, Enrico P, Moltrasio C, Delvecchio G, Brambilla P. Augmentation with atypical antipsychotics for treatment-resistant depression. J Affect Disord. 2021, 280:45-53. 10.1016\/j.jad.2020.11.006","journal-title":"J Affect Disord"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy SH","year":"2016","unstructured":"Kennedy SH, Lam RW, McIntyre RS, et al.. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016, 61:540-60. 10.1177\/0706743716659417","journal-title":"Can J Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson JC","year":"2009","unstructured":"Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009, 166:980-91. 10.1176\/appi.ajp.2009.09030312","journal-title":"Am J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/494768-comparative-augmentative-efficacy-of-second-generation-antipsychotics-in-adult-treatment-resistant-depression-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:38:36Z","timestamp":1779863916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/494768-comparative-augmentative-efficacy-of-second-generation-antipsychotics-in-adult-treatment-resistant-depression-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.109712","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}